Abstract
Background
Aortic valve calcification (AVC) and mitral annual calcification (MAC) may progress to aortic and mitral stenosis in older adults. The role of major mineralization regulators MGP (matrix Gla protein), FGF‐23 (fibroblast growth factor‐23), and fetuin‐A in long‐term progression of AVC and MAC remains unexamined.
Methods
We measured blood levels of dp‐ucMGP (n=2663) at study baseline and evaluated these concurrently with prior baseline measures of FGF‐23 (n=6547) and fetuin‐A (n=2550) in relation to AVC and MAC quantified on ≤3 serial computed tomography scans over 9.4 (interquartile range, 9.0–9.8) years in MESA (Multi‐Ethnic Study of Atherosclerosis). We used linear mixed‐effects models to simultaneously assess the incidence and progression of AVC and MAC.
Results
Our objective was to investigate the association of circulating dephosphorylated–uncarboxylated (dp‐uc) MGP, reflecting vitamin K deficiency/diminished MGP anticalcific capacity; FGF‐23, a phosphaturic hormone; and fetuin‐A, a calcium‐phosphate solubilizer, with long‐term incidence and progression of AVC and MAC. After adjustment for demographic and clinical characteristics, dp‐ucMGP was associated with higher annual incidence/progression of AVC (0.94 [95% CI, 0.42, 1.46] Agatston units/y) and MAC (3.90 [95% CI, 1.06, 6.74] Agatston units/y); FGF‐23 with higher annual incidence/progression of MAC (2.61 [95% CI, 0.50, 4.72] Agatston units/y); and fetuin‐A with lower annual incidence/progression of AVC (−0.89 [95% CI, −1.55, −0.23] Agatston units/y (all per SD increment in regulator).
Conclusions
In this multiethnic sample, dp‐ucMGP and FGF‐23 were associated with higher, and fetuin‐A with lower, long‐term incidence/progression of valvular or annular calcification. This has implications for therapeutic trials of calcific valvular disease, particularly targeting vitamin K supplementation to individuals with higher dp‐ucMGP levels.
Keywords: aortic valve calcification, fetuin A, fibroblast growth factor 23, matrix Gla Protein, mitral annular calcification
Subject Categories: Biomarkers
Nonstandard Abbreviations and Acronyms
- AS
aortic stenosis
- AU
Agatston units
- AVC
aortic valve calcification
- CAVD
calcific aortic valve disease
- dp‐uc
dephosphorylated–uncarboxylated
- FGF‐23
fibroblast growth factor‐23
- MAC
mitral annular calcification
- MESA
Multi‐Ethnic Study of Atherosclerosis
- MGP
matrix Gla protein
Research Perspective.
What Is New?
Higher dp‐ucMGP (dephosphorylated–uncarboxylated matrix Gla protein) was associated with increased aortic valve and mitral annular calcification, higher fibroblast growth factor 23 was associated with increased mitral annular calcification, and higher fetuin‐A was associated with decreased aortic valve calcification.
What Question Should Be Addressed Next?
Whether vitamin K supplementation in the context of high dp‐ucMGP levels prevents progression of valvular calcification requires further study.
Aortic valve and mitral annular calcification (AVC and MAC, respectively) are progressive disorders that can lead to serious valvular dysfunction. 1 Severe calcific aortic stenosis (AS) has a cumulative frequency of 3.7% to 4.7% in older adults, and once symptomatic, portends a high mortality rate unless the valve is replaced. 1 The reported prevalence of severe calcific mitral stenosis is 5% to 42%, depending on demographic characteristics and method of ascertainment. 2 Atrial fibrillation and stroke are documented consequences of MAC. 3 Once advanced mitral stenosis occurs, heart failure is another complication, with relief of valvular obstruction attainable only surgically. 4 No medical therapies are available for AVC or MAC or related valvular disease.
Risk factors for cardiac calcification include dyslipidemia, inflammation, and mineral dysregulation. 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 Randomized trials of statins were null for prevention of severe AS, 13 as were 2 clinical trials targeting mineral metabolism to reduce AVC progression. 13 , 14 , 15 The first evaluated the osteoclast inhibitor denosumab and the bisphosphonate alendronate, and the second studied the combination of vitamin K2, a cofactor for anticalcific proteins, and bone‐stabilizing vitamin D. 14 , 15 Still, because these trials did not select individuals with calcific aortic valve disease (CAVD) and losteoporosis or low vitamin K, they leave open the question of efficacy in these targeted settings.
Molecular regulators of tissue calcification are attractive candidates for study, but gaps remain about their contributions to CAVD or MAC. Three principal regulators of extraosseous calcium deposition are MGP (matrix Gla protein), FGF‐23 (fibroblast growth factor‐23 and fetuin‐A (Figure 1). 16 , 17 , 18 Secreted by vascular smooth muscle and valvular interstitial cells, MGP is considered the strongest inhibitor of ectopic mineralization. 19 Proper function of MGP requires phosphorylation and vitamin K–dependent carboxylation. Circulating dephosphorylated–uncarboxylated (dp‐uc) MGP is a sensitive measure of vitamin K deficiency that best reflects diminished anticalcific activity on the basis of documented associations with vascular calcification, cardiovascular disease, and death. 20 , 21 , 22 Valvular MGP expression was low in severe AS, and dp‐ucMGP high in symptomatic AS, implicating MGP in CAVD. 23
Figure 1. Mineral regulators in AVC and MAC incidence and progression.

Fetuin‐A, a protein synthesized by the liver, solubilizes elevated CaPhos levels in the blood. When phosphate levels rise, FGF‐23, which is synthesized by bone, increases urinary phosphate by decreasing calcitriol formation and downregulating Na‐Phos transport. MGP from VSMCs and endothelial cells decreases CaPhos precipitation and downregulates BMP2. When anticalcific mechanisms are overwhelmed or fail, this contributes to progressive calcification of the aortic and mitral valves. 1,25OH2D, 1,25‐dihydroxyvitamin D; AVC indicates aortic valve calcification; BMP, bone morphogenic protein; CaPhos, calcium phosphate; FGF‐23, fibroblast growth factor‐23; MAC, mitral annular calcification; MGP, matrix Gla protein; Na‐Phos, sodium phosphate; and VSMC, vascular smooth muscle cell.
FGF‐23 regulates phosphate homeostasis by decreasing proximal tubule reabsorption and suppressing synthesis of vitamin D3. 24 FGF‐23 has been variably linked to cardiac calcification, showing positive associations with coronary artery calcification (CAC) progression, as well as MAC, though not AVC, progression over short‐term follow‐up in MESA (Multi‐Ethnic Study of Atherosclerosis). 9 , 25 Among patients with advanced AS, however, FGF‐23 was a foremost predictor of death or heart failure–related hospital admission. 26
Fetuin‐A is a prime solubilizer of calcium and phosphate, but also engages the insulin receptor to produce insulin resistance. 27 Upon binding of calciprotein particles, fetuin‐A has been experimentally shown to slow crystallization and thereby prevent plate and needle‐like conformations within aortic valve leaflets that can progress to severe AS. 28 However, studies evaluating the relationship of fetuin‐A with short‐ to medium‐term CAVD progression in patients with mild‐to‐moderate AS have yielded mixed findings. In MESA, prior evaluation of circulating fetuin‐A showed an inverse association with short‐term progression of CAC, but not AVC or MAC. 9 , 29 We tested the hypothesis that dp‐ucMGP, FGF‐23, and fetuin‐A would be independently associated with long‐term progression of cardiac calcification in this multiethnic cohort.
METHODS
Study Population and Cardiac Computed Tomography
The authors will share their analysis on request, and data are available at https://www.mesa‐nhlbi.org. MESA methods have been previously described. 30 Briefly, 6 institutional review board–approved centers across the United States participated in enrolling 6814 men and women aged 45 to 84 years in 2000 through 2002 (examination 1). Participants were self‐reported White, Black, Hispanic/Latino, or Chinese individuals who signed informed consent documentation. The analytical sample comprised participants who completed a noncontrast cardiac computed tomography (CT) scan (n=6812), had available Examination 1 (baseline) mineral regulator measures (n=6678), and were not receiving warfarin (n=24). For dp‐ucMGP, participants who completed CT scans in Examinations 1 and 5 and had available plasma specimens were selected for measurement. For FGF‐23, all baseline participants with available serum specimens underwent measurement, whereas for fetuin‐A, participants with Examination 1 and Examination 3 scans and available serum specimens had measurement performed. 29
Participants underwent up to 3 CT scans at baseline (2000–2002), Exam 2 or 3 (2002–2004 or 2004–2006, randomly divided between the Exams), and Exam 5 (2010–2012) (Figure 2). Electron beam CT and multidetector CT were used in the baseline examination, but multidetector CT was preferentially used thereafter. CT scans were performed under a standardized protocol, with methods, quality control, and equivalence across scanner types detailed previously. 31 , 32 Uniform Agatston scoring of AVC or MAC for all sites was performed by the MESA CT reading center in a semiautomated fashion in duplicate and averaged, exhibiting high within‐ and between‐reader agreement. 31 AVC score was derived from the sum of calcific foci within the aortic valve leaflets, excluding the aortic wall, while MAC score was calculated from the sum of calcific foci within the mitral annulus, excluding the leaflets. AVC or MAC >0 at baseline was defined as prevalent calcification. AVC or MAC >0 at follow‐up without baseline calcification was defined as incident AVC, and progression of AVC or MAC as a positive difference between scans. 9 Follow‐up was determined from the dates of the initial and last available CT scan.
Figure 2. Flow diagram of participants with calcification and biomarker measures at serial examinations in MESA.

AVC indicates aortic valve calcification; dp‐ucMGP, dephosphorylated‐uncarboxylated matrix Gla protein; FGF‐23, fibroblast growth factor‐23; MAC, mitral annular calcification; and MESA, Multi‐Ethnic Study of Atherosclerosis.
Regulators of Calcification
dp‐ucMGP was measured in fresh or up to twice‐thawed baseline plasma specimens stored at −80 °C after collection. Measurement was performed using the IDS‐iSYS Multi‐Discipline Automated System (Bolden Business Park, South Tyneside, UK), with an average concentration of 480 pmol/L. Intra‐ and interassay coefficients of variation were 4.0% and 4.5%, respectively. Approximately 14% of the samples were under the quantification limit (<300 pmol/L). These were set at half this limit (150 pmol/L) for analytic purposes to reduce bias. 33 FGF‐23 was measured in baseline serum specimens as previously described (Kainos Laboratories, Tokyo, Japan). 34 The coefficients of variation for low and high controls were 12.4% and 6.7%, respectively. 25 Measurement of fetuin‐A was performed in baseline serum specimens as previously described (Epitope Diagnostics, San Diego, CA). 29 The mean intra‐assay coefficient of variation was 3.0% and the mean interassay coefficients of variation were 5.3% and 4.8% at low and high concentrations, respectively.
Covariates
Sex, race and ethnicity, cigarette smoking, alcohol use, educational attainment and medication information was reported by participants on a baseline questionnaire. Heavy alcohol consumption was defined as >14 beverages/wk (men) and >7 beverages/wk (women). Total energy intake (kcal/d) was defined from a food frequency questionnaire. Categorical diet quality was quantified from higher consumption of fruits and vegetables, whole grains, and fish, and lower consumption of sodium and lower sugary beverages, on the food frequency questionnaire, as “ideal,” 4 , 5 “intermediate,” 2 , 3 or “poor” (0–1), as per the American Heart Association's Life's Simple 7. 35 Body mass index was calculated as weight (kg) divided by height squared (m2). Systolic blood pressure was determined by averaging the last 2 of 3 seated measurements on an automated oscillometric sphygmomanometer. Diabetes was defined as fasting glucose ≥126 mg/dL or reporting using a medication to lower glucose. Low‐density lipoprotein cholesterol was calculated from the Friedewald equation when specimens had triglycerides of <400 mg/dL. The Chronic Kidney Disease‐Epidemiology Collaboration 2009 equation was used for the estimated glomerular filtration rate (eGFR). hsCRP (high‐sensitivity C‐reactive protein) was measured with a standard assay (Dade Behring Inc., Deerfield, IL), as previously described. 36 Baseline CT determinations of coronary artery calcium, bone mineral density (mg/cm3) of the thoracic vertebrae, and liver steatosis were performed using standard methods, as previously described. 8 , 37 , 38 Liver steatosis was defined as a ratio of liver‐to‐spleen density of <1.0 Hounsfield units, and categorized as mild (0.7–1.0 Hounsfield units), moderate (0.5–0.7 Hounsfield units), and severe (<0.5 Hounsfield units). 39
Statistical Analysis
Cross‐sectional associations of mineral regulators with baseline characteristics were assessed by Spearman correlation coefficients or the Wilcoxon rank‐sum test, as appropriate. Follow‐up was determined from the dates of the baseline and last available CT scan. We simultaneously evaluated prevalence, incidence, and progression of AVC and MAC in all participants with or without any calcification at baseline using linear mixed‐effects models. Each model included a participant‐specific random intercept to account for between‐person heterogeneity and an autoregressive correlation structure of order 1 to model serial correlation among repeated measurements over time. Models were estimated using the lme function from the nlme package in R (R Foundation for Statistical Computing, Vienna, Austria), which allows simultaneous specification of random effects and structured within‐subject correlation. To obtain inference that is robust to potential misspecification of the working covariance structure, we computed cluster‐robust standard errors using the coef_test function from the clubSandwich package, clustering on participant ID. The dependent variable was the repeated measure of AVC or MAC. The independent variable was dp‐ucMGP, FGF‐23, or fetuin‐A and its interaction with time from baseline, with time from baseline also included as a main effect in the model. This interaction parameter gives the rate of change of AVC or MAC over time per change in biomarker concentration. For a positive change in calcification over time, this may reflect incidence or progression. Calcification measures were largely zero‐weighted and skewed but were analyzed in their original scale as the distribution becomes asymptotically normal for a large sample size. 8 , 9 , 40 We analyzed continuous levels of dp‐ucMGP, FGF‐23, and fetuin‐A, with effect estimates reported per SD increment. Models were initially unadjusted, and then serially adjusted for confounders or mediators, the roles of which are depicted in directed acyclic graphs (Figures S1A–S1C). Model 1 adjusted for age, sex, race and ethnicity, scanner type, and site. Model 2 (main model) additionally adjusted for education, body mass index, smoking, systolic blood pressure, antihypertensive therapy, diabetes, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, statin use, and eGFR. Linearity was assessed by examining smooth‐term generalized additive mixed‐model plots, fitted with the gamm function from the mgcv package, for the model 2 associations of mineral regulators with AVC or MAC at Exams 1 (baseline), 2/3, and 5. In exploratory models, we examined the impact of additionally adjusting for diet quality and total energy intake, alcohol use, hsCRP, and serum calcium and phosphate, which in the case of FGF‐23 can be considered partial intermediates. We conducted exploratory analyses assessing the impact of removing extreme outliers (>5 SD) with negative values (decreases) of calcification over time. These did not influence the findings for AVC or MAC, except for 1 participant with an extreme negative change in AVC (3113 Agatston units [AU] in Exam 1, 3238 AU in Exam 2, and 197 AU in Exam 5) whose inclusion substantially weakened the point estimates for dp‐ucMGP and FGF‐23 (the participant lacked a fetuin‐A measurement). The Exam 5 AVC value, which was deemed to be a measurement error, was removed from the analysis. For dp‐ucMGP, we explored fitting values below the lower quantification limit (<300 pmol/L) using a truncated log‐normal distribution, instead of assigning a value of 150 pmol/L, but this did not alter the findings. Further exploratory analyses included adjusting the associations of dp‐ucMGP with incidence/progression of AVC and MAC for each other at baseline and for baseline CAC, given the vascular smooth muscle cell provenance of dp‐ucMGP; adjusting the association of FGF‐23 for baseline bone mineral density, given this regulator's production by osteocytes; and adjusting the association of fetuin‐A for baseline liver steatosis, given this molecule's hepatic source. Finally, we performed exploratory testing for effect modification of biomarker associations by fitting 3‐way interaction terms for each of the following covariates: continuous age (also stratified by ≥65 versus <65 years), sex, race and ethnicity, diabetes, continuous eGFR (also stratified by <60 versus ≥60 mL/min per 1.73 m2) and, in the case of fetuin‐A, also diabetes. Statistical significance was a 2‐tailed P<0.05 for main analyses, and a 2‐tailed P<0.01 for 3‐way interactions. We did not correct for multiple testing but interpreted findings considering previous literature and biologic associations. Analyses were performed in R. Forest plots were generated with Prism 9.1.0 (GraphPad Software, La Jolla, CA).
RESULTS
Baseline Characteristics and Univariable Associations of Biomarkers
At baseline, 6678 participants had available AVC or MAC and at least 1 of the mineral regulator measures. The sample had a mean age of 62±10 years, and 53% were women; the racial and ethnic composition was 38.5% White, 27.5% Black, 22.0% Hispanic/Latino, and 12.0% Chinese individuals. Participants who underwent dp‐ucMGP and FGF‐23 measurements had a generally healthier cardiovascular risk profile and less cardiac calcification than participants who did not, although this was not the case for participants with and without fetuin‐A, who were more similar (Table S1). Cross‐sectional associations of the 3 mineral regulators with baseline characteristics and with each other are presented in Table 1. dp‐ucMGP and FGF‐23 were positively, and fetuin‐A negatively, associated with age and hypertension. The reverse was true for eGFR, where dp‐ucMGP was negatively, and fetuin‐A positively, correlated with this covariate. Whereas FGF‐23 was higher in men, dp‐ucMGP and fetuin‐A were higher in women. FGF‐23 and fetuin‐A were highest in White individuals and correlated positively with serum calcium and phosphate, while dp‐ucMGP was highest in Hispanic/Latino individuals and correlated (negatively) only with phosphate. All 3 regulators correlated with dietary energy intake, body mass index, lipid measures, and hsCRP (all positively), as well as CAC (all positively except fetuin‐A). dp‐ucMGP levels were also higher with poor diet quality and heavy alcohol use. There were correlations of dp‐ucMGP (negative) and fetuin‐A (positive) with thoracic bone mineral density, and both were positively related to liver steatosis. Finally, dp‐ucMGP was positively correlated with FGF‐23, but neither dp‐ucMGP nor FGF‐23 was correlated with fetuin‐A.
Table 1.
Cross‐Sectional Associations of dp‐ucMGP, FGF‐23, and Fetuin‐A With Baseline Characteristics
| Characteristic | dp‐ucMGP, pmol/L (n=2663) | FGF‐23, pg/mL (n=6531) | Fetuin A, g/L (n=2892) | |||
|---|---|---|---|---|---|---|
| Spearman's rho or median* (IQR) | P value | Spearman's rho or median* (IQR) | P value | Spearman's rho or median* (IQR) | P value | |
| Age | 0.21 | <0.001 | 0.10 | <0.001 | −0.17 | <0.001 |
| Sex | <0.001 | <0.001 | 0.001 | |||
| Male | 413.2 (333.7–504.2) | 38.3 (31.3–47.1) | 0.47 (0.40–0.54) | |||
| Female | 432.8 (349.5–531.1) | 37.1 (29.7–45.8) | 0.48 (0.41–0.55) | |||
| Race and ethnicity | <0.001 | <0.001 | <0.001 | |||
| White | 447.5 (360.3–544.2) | 39.2 (31.7–48.4) | 0.49 (0.42–0.55) | |||
| Black | 372.6 (150–455.7) | 37.0 (29.7–45.3) | 0.45 (0.39–0.52) | |||
| Hispanic | 463.6 (378.2–554.8) | 36.0 (29.1–44.0) | 0.47 (0.41–0.55) | |||
| Chinese | 408.1 (342.0–482.7) | 37.5 (30.8–46.1) | 0.48 (0.42–0.55) | |||
| Scanner type | 0.154 | <0.001 | 0.277 | |||
| Electron beam CT | 423.8 (342.0–514.1) | 36.7 (29.7–45.3) | 0.48 (0.41–0.54) | |||
| Multidetector CT | 427.7 (343.9–523.3) | 38.9 (31.3–47.9) | 0.47 (0.40–0.54) | |||
| Education | <0.001 | <0.001 | 0.758 | |||
| High school or less | 445.4 (352.4–539.9) | 37.1 (29.9–45.3) | 0.47 (0.41–0.54) | |||
| Greater than high school | 416.8 (340.3–507.8) | 38.1 (30.8–47.3) | 0.47 (0.41–0.54) | |||
| Body mass index | 0.18 | <0.001 | 0.09 | <0.001 | 0.06 | 0.003 |
| Diet quality | 0.015 | 0.077 | 0.728 | |||
| Poor | 432.9 (347.4–527.2) | 38.0 (30.7–46.8) | 0.47 (0.41–0.55) | |||
| Intermediate | 416.4 (337.7–506.8) | 37.4 (30.4–46.3) | 0.47 (0.41–0.54) | |||
| Ideal | 404.0 (339.8–512.3) | 32.7 (29.5–38.2) | 0.47 (0.39–0.51) | |||
| Total energy intake | 0.05 | 0.018 | 0.04 | 0.004 | 0.04 | 0.004 |
| Smoking | 0.128 | <0.001 | 0.492 | |||
| Never | 431.5 (343.1–516.5) | 38.0 (30.6–46.6) | 0.47 (0.41–0.54) | |||
| Former | 423.1 (345.1–523.5) | 38.2 (31.0–47.3) | 0.47 (0.40–0.54) | |||
| Current | 431.5 (343.1–516.5) | 35.2 (28.5–43.5) | 0.47 (0.40–0.54) | |||
| Heavy alcohol use | 0.011 | 0.983 | 0.452 | |||
| No | 423.2 (342.1–517.0) | 37.7 (30.5–46.5) | 0.47 (0.41–0.54) | |||
| Yes | 457.7 (370.4–555.9) | 38.1 (30.7–46.7) | 0.46 (0.41–0.54) | |||
| Systolic blood pressure | 0.08 | <0.001 | 0.06 | <0.001 | −0.05 | 0.006 |
| Antihypertensive medication | 0.016 | <0.001 | 0.019 | |||
| No | 421.5 (341.7–510.3) | 36.6 (29.8–44.6) | 0.48 (0.41–0.54) | |||
| Yes | 428.7 (345.2–535.6) | 39.9 (31.7–50.0) | 0.46 (0.4–0.54) | |||
| Diabetes | 0.594 | 0.117 | 0.032 | |||
| No | 425.8 (344.0–518.8) | 37.7 (30.5–46.3) | 0.47 (0.41–0.54) | |||
| Yes | 416.3 (338.6–514.2) | 37.7 (30.5–48.8) | 0.46 (0.40–0.53) | |||
| Low‐density lipoprotein cholesterol | 0.02 | 0.434 | 0.01 | 0.431 | 0.06 | 0.002 |
| High‐density lipoprotein cholesterol | −0.06 | <0.001 | −0.11 | <0.001 | −0.05 | 0.007 |
| Triglycerides | 0.16 | <0.001 | 0.10 | <0.001 | 0.20 | <0.001 |
| Statin | 0.049 | <0.001 | 0.066 | |||
| No | 423.8 (342.0–514.1) | 37.4 (30.3–46.0) | 0.47 (0.41–0.54) | |||
| Yes | 429.2 (351.7–539.9) | 39.9 (31.6–49.1) | 0.46 (0.39–0.54) | |||
| eGFR | −0.16 | <0.001 | −0.24 | <0.001 | 0.04 | 0.016 |
| High‐sensitivity C‐reactive protein | 0.19 | <0.001 | 0.03 | 0.006 | 0.05 | 0.012 |
| Serum calcium | −0.01 | 0.514 | 0.10 | <0.001 | 0.12 | <0.001 |
| Serum phosphate | −0.06 | 0.002 | 0.10 | <0.001 | 0.04 | 0.018 |
| Coronary artery calcium | 0.11 | <0.001 | 0.12 | <0.001 | −0.10 | <0.001 |
| Bone mineral density | −0.16 | <0.001 | −0.02 | 0.144 | 0.05 | 0.010 |
| Liver steatosis | 0.003 | 0.581 | <0.001 | |||
| None | 424.5 (341.2–516.2) | 37.7 (30.5–46.3) | 0.46 (0.40–0.53) | |||
| Mild | 456.1 (370.9–541.1) | 38.6 (30.4–47.9) | 0.50 (0.43–0.57) | |||
| Moderate | 437.8 (340.8–497.7) | 38.5 (31.0–47.4) | 0.51 (0.44–0.59) | |||
| Severe | 467.3 (403.0–604.2) | 34.4 (29.1–48.0) | 0.59 (0.52–0.64) | |||
| dp‐ucMGP | N/A | N/A | 0.11† | <0.001 | −0.04† | 0.165 |
| FGF‐23 | 0.11 | <0.001 | N/A | N/A | 0.02 | 0.347 |
| Fetuin‐A | −0.04 | 0.165 | 0.02† | 0.347 | N/A | N/A |
AVC indicates aortic valve calcification; CT, computed tomography; dp‐ucMGP, dephosphorylated‐uncarboxylated matrix Gla protein; eGFR, estimated glomerular filtration rate; FGF‐23, fibroblast growth factor‐23; MAC, mitral annular calcification; and N/A, not applicable.
For dp‐ucMGP in pmol/L; for FGF‐23 in pg/mL; for fetuin‐A in g/L.
For dp‐ucMGP and FGF‐23, n=2599 had overlapping measures; for dp‐ucMGP and fetuin‐A, n=1395 had overlapping measures; for FGF‐23 and fetuin‐A, n=2783 had overlapping measures.
Incidence and Progression of AVC and MAC
Participants with at least 1 of the mineral regulators were followed for a median of 9.4 (interquartile range, 9.0–9.8) years. Incidence and progression of AVC and MAC are shown in Table 2. AVC and MAC increased longitudinally in the study sample, with rare instances of decreases, which may reflect measurement variability or error (Figure 3).
Table 2.
Prevalence, Incidence, and Annualized Change in AVC and MAC Among Participants With at Least 1 Follow‐Up Computed Tomography Scan
| Cardiac calcification | Prevalence, incidence, or progression values (n=6277) |
|---|---|
| AVC | |
| Prevalence, n (% [95% CI]) | 805 (12.8 [12–13.7]) |
| Cumulative incidence, n (% [95% CI]) | 428 (7.8 [7.1–8.6]) |
| Incidence rate (95% CI), per 100 person‐years | 1.28 (1.16, 1.40) |
| Annualized change, AU | |
| Mean±SE* | 2.99±0.28 |
| Median (interquartile range) | 0 (0–0) |
| Annualized change in group with prevalent AVC, AU | |
| Mean±SE* | 17.91±2.24 |
| Median (interquartile range) | 3.1 (0–16.0) |
| MAC | |
| Prevalence, n (% [95% CI]) | 572 (9.1 [8.4–9.9]) |
| Cumulative incidence, n (% [95% CI]) | 584 (10.2 [9.5–11.1]) |
| Incidence rate (95% CI), per 100 person years | 1.68 (1.54–1.81) |
| Annualized change, AU | |
| Mean±SE* | 10.25±0.86 |
| Median (interquartile range) | 0 (0–0) |
| Annualized change in group with prevalent MAC, AU | |
| Mean±SE* | 96.02±9.80 |
| Median (interquartile range) | 14.7 (0–69.8) |
AU indicates Agatston units; AVC, aortic valve calcification; and MAC, mitral annular calcification.
Estimates reported from linear mixed model.
Figure 3. Spaghetti plots indicating the trajectory of AVC and MAC from serial examinations in MESA for which computed tomography quantification of calcification was available.

A positive trajectory indicates increased calcification score. A negative trajectory indicates decreased calcification score. AVC indicates aortic valve calcification; MAC, mitral annular calcification; MESA, Multi‐Ethnic Study of Atherosclerosis; and N/A, not available.
Mineral Regulators and Change in Valvular/Annular Calcification
The associations of mineral regulators with AVC and MAC outcomes are shown in Figure 4A and 4B, respectively. dp‐ucMGP was significantly associated with increased long‐term AVC incidence and progression in unadjusted and minimally and fully adjusted models (Figure 4A). In the fully adjusted model, every SD (177.7 pmol/L) increment in dp‐ucMGP was associated with a 0.94 AU/y higher rate of incidence or progression of AVC. This association persisted with additional adjustment for diet quality and total energy intake, alcohol use, hsCRP, or calcium and phosphate (not shown). FGF‐23 levels were not associated with AVC at any level of adjustment. Fetuin‐A levels did show an inverse association with AVC across levels of adjustment, such that in the fully adjusted model every SD (0.1 g/L) increment corresponded to a 0.89 AU/y lower rate of AVC incidence or progression. This association was not materially influenced by additional adjustment for diet quality and total energy intake, alcohol use, hsCRP, or calcium and phosphate.
Figure 4. Associations of mineral metabolism measures with incidence and progression of (A) AVC and (B) MAC.

β coefficients are calculated from the interaction term between baseline level of the biomarker and time; these coefficients are per SD increment in level of the biomarker. Model 0: unadjusted; model 1: adjusted for age, sex, race and ethnicity, scanner type, and site; model 2: adjusted for model 1 covariates and education, body mass index, systolic blood pressure, antihypertensive therapy, diabetes, smoking, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, statin use, and estimated glomerular filtration rate. SDs: dp‐ucMGP, 177.7 pmol/L; FGF‐23, 18.4 pg/mL; fetuin‐A, 0.1 g/L. AU indicates Agatston units; AVC, aortic valve calcification; dp‐ucMGP, dephosphorylated‐uncarboxylated matrix Gla protein; FGF‐23, fibroblast growth factor‐23; and MAC, mitral annular calcification.
dp‐ucMGP was likewise significantly associated with higher long‐term MAC incidence and progression across all levels of adjustment. In the fully adjusted model, each SD increment was associated with a 3.90 AU/y higher rate of MAC incidence and progression (Figure 4B). This association persisted with additional adjustment for diet quality and total energy intake, alcohol use, hsCRP, or calcium and phosphate. FGF‐23 also showed a significant relationship with MAC in all models, with the fully adjusted association corresponding to a 2.61 AU/y higher rate of MAC incidence or progression for every SD (18.4 pg/mL) increment in FGF‐23. There was no association of fetuin‐A levels with MAC at any level of adjustment. For the dp‐ucMGP relationship, additional adjustment for FGF‐23 in the fully adjusted model had no impact on the risk estimate.
As shown in Figure S2, main‐model associations for mineral regulators were largely linear across examinations. These generally supported linear modeling of the relationships, although there was some deviation in examination 2/3 for dp‐ucMGP and AVC, and especially fetuin‐A and MAC.
In additional exploratory analyses, further adjustment of models for dp‐ucMGP and incidence/progression of AVC or MAC for each other (Figure S3) or for CAC at baseline (Figure S4) did not materially change the results, except for substantial attenuation of the association of dp‐uc MGP with AVC after adjustment for baseline MAC. Additional adjustment of FGF‐23 models for baseline thoracic bone mineral density (Figure S5) or fetuin‐A models for baseline liver steatosis (Figure S6) did not affect the findings.
Evaluation of 3‐way interactions of mineral regulators and time with age, sex, race and ethnicity, eGFR and (for fetuin‐A) diabetes did not reveal evidence of effect modification at the P<0.01 level. There were 4 regulator‐by‐time‐by‐covariate interactions that met the P<0.05 level, of which 2 were observed for both AVC and MAC (Table S2). These latter interactions suggested a stronger positive association of dp‐ucMGP with each outcome among participants aged ≥65 years or with eGFR <60 mL/min per 1.73 m2.
DISCUSSION
This study evaluated the association of the major mineral regulators dp‐ucMGP, FGF‐23, and fetuin‐A with long‐term incidence and progression of cardiac valvular or annular calcification in a multiethnic sample. Higher dp‐ucMGP levels were significantly associated with greater incidence and progression of AVC and MAC, a relationship that was also observed for FGF‐23 with MAC but not AVC. By contrast, higher fetuin‐A levels were significantly associated with lower incidence and progression of AVC but did not show an association with MAC.
The observed associations of mineral regulators with incidence and progression of valvular/annular calcification largely persisted across a range of exploratory analyses adjusting for the alternative type of baseline cardiac calcification or tissue sources. Only in the case of dp‐ucMGP's association with incidence and progression of AVC did adjustment for baseline MAC lead to substantive attenuation of the association. However, MAC, like AVC, is but 1 of many tissue sources of MGP, which is produced in the vasculature, bone, cartilage, lungs, and kidneys, 41 and the major determinant of circulating dp‐ucMGP concentration is vitamin K level. 19 Accordingly, adjusting for MAC in this analysis is likely to primarily reflect controlling for a downstream consequence of dp‐ucMGP rather than for its main tissue source. As such, the sizable attenuation observed for dp‐ucMGP and AVC after MAC adjustment may reflect a more dominant association of this regulator with calcification at the mitral annulus than the aortic valve.
Mineral metabolism is recognized to play a role in cardiovascular disease, prompting a focus on molecular regulators of mineral processes. 19 , 25 , 42 Clinical studies have evaluated 3 prominent regulators or their measures in circulation—dp‐ucMGP, FGF‐23, and fetuin‐A—documenting associations with vascular calcification or cardiovascular disease events. 21 , 37 , 43 , 44 , 45 In people with prevalent coronary heart disease, fetuin‐A showed inverse cross‐sectional associations with MAC and, among those without diabetes, AS. 46 Among patients with AVC or AS, low fetuin‐A was previously related to higher short‐term progression of AVC at serial CT scans 12.6 months apart, 47 but baseline levels of this regulator were not associated with progression of CAVD in a larger sample with on average moderate AS after a mean follow‐up of 3 years. 48 In community‐dwelling older adults, both FGF‐23 and fetuin‐A were cross‐sectionally associated with echocardiographic MAC, though not AVC, but among middle‐aged to older adults from MESA, only FGF‐23 was related to MAC incidence and progression over the short term (median, 2.4 years). 5
Prior assessment of MGP and valvular calcification has involved its uncarboxylated and dephosphorylated species. Circulating uncarboxylated MGP showed divergent cross‐sectional associations with MAC in the presence (positive) and absence (inverse) of diabetes. 49 Dephosphorylated MGP was not associated with progression of AS in the context of a clinical trial of rosuvastatin. 50 But there was evidence of effect modification by age, such that higher dephosphorylated MGP related to higher AS progression in participants aged ≤57 years. 50 Neither study evaluated dp‐ucMGP, however, the species most closely linked to vitamin K status or tissue‐level anticalcific actions. 51
To our knowledge, this is the first investigation of all 3 regulators in relation to long‐term progression of AVC and MAC, and also the first clinical study to evaluate dp‐ucMGP with respect to valvular or annular calcification in an epidemiological setting. The associations of dp‐ucMGP with long‐term incidence and progression of AVC and MAC in a multiethnic cohort free of clinical cardiovascular disease at baseline are therefore novel, with implications for the potential prevention of related calcific valvular disorders. We also confirm that the previously documented association of FGF‐23 with short‐term MAC progression in this cohort 9 holds when extended long term and newly identify a significant inverse association of fetuin‐A with long‐term incidence and progression AVC (though not MAC), which was previously not found to be significant over the short term. 9
The magnitudes of association detected between mineral regulators and incidence and progression of valvular/annular calcification were modest. For dp‐ucMGP, these corresponded to 31% (0.94/2.99 AU) and 38% (3.9/10.25 AU) of the annual change seen in the overall cohort for AVC and MAC, respectively. For FGF‐23 and MAC, the association corresponded to 25% (2.61/10.25 AU), while for fetuin‐A and AVC, the association corresponded to 30% (0.89/2.99 AU). Still, because biomarker levels were not measured serially over the follow‐up period, these associations likely represent underestimates. Moreover, given that AVC and MAC progression are gradual processes, the cumulative impact of modifying levels of these regulators over extended periods could be substantial.
The biology of MGP is closely dependent on vitamin K. Carboxylation of glutamate residues requires reduced vitamin K as a cofactor. 52 Decreased carboxylation of MGP in the context of nutritional deficiency of vitamin K or depletion of reduced vitamin K from warfarin antagonism leads to decreased functionality of MGP as a calcification inhibitor. 52 Multiple observational and retrospective studies have shown that vitamin K antagonist therapy may be associated with increased AVC and progression of AS. 53 , 54
Vitamin K supplementation to modify CAVD has been evaluated in clinical trials. A single‐center, open‐label, proof‐of‐concept randomized trial showed significantly lower change in AVC volume after 1 year of vitamin K1 supplementation compared with placebo. 55 The association persisted when adjusting for age but not for mean valve gradient. A larger, multicenter double‐blind randomized trial found no statistically significant difference in 24‐month progression of AVC Agatston scores in older men with AVC of >300 AU receiving vitamin K2 and vitamin D versus placebo, despite significant reductions in dp‐ucMGP levels. 15 However, the trial did not target patients with AVC and vitamin K deficiency (high dp‐ucMGP), leaving open the question of whether targeted intervention could show efficacy. Nor did it evaluate the impact on progression of milder AVC or MAC.
Exploratory analyses of effect modification suggested stronger positive associations of dp‐ucMGP with both AVC and MAC in participants aged ≥65 years or with eGFR <60 mL/min per 1.73 m2, groups with higher dp‐ucMGP levels. These findings may support the concept of focusing supplementation trials of vitamin K on individuals with higher dp‐ucMGP levels.
As relates to FGF‐23's association with incidence and progression of MAC, but not AVC, this mirrors the stronger relationship between chronic kidney disease, with which FGF‐23 is particularly associated, and calcification of the mitral annulus over calcification of the aortic valve. 5 Whether the relationship of FGF‐23 with cardiac and vascular calcification is attributable to direct biological actions of the hormone has been questioned, 56 but recent experimental evidence supports roles for FGF‐23–related pathways, potentiated by klotho deficiency. 57 Persistence of the FGF‐23 association with MAC despite adjustment for various potential confounders here supports additional study of FGF‐23 biology to determine whether viable options exist for therapeusis of calcific mitral valve disease.
The finding of an inverse association of fetuin‐A with incidence and progression of AVC supports that the dominant impact of this protein in healthy individuals is to protect against CAVD. No evidence of interaction by diabetes was detected, but glucose dysregulation was less prevalent than in a prior cohort with coronary heart disease. 58 The basis for the preferential association of fetuin‐A with AVC over MAC will require further investigation. Therapeutic manipulation of fetuin‐A levels for CAVD prevention, however, must account for the protein's actions on insulin resistance.
Several limitations of our study merit attention. We obtained measures in participants with follow‐up scans or available blood specimens. These participants, particularly those with dp‐ucMGP and FGF‐23 measures, represent a healthier subset from the cohort. Whether the prospective associations observed between these regulators and valvular/annular calcification differ in individuals with more advanced disease requires independent study. We did not correct for multiple testing because of substantial biological and clinical data supporting a role for these regulators in clinical valvular disease, prioritizing minimization of the false‐negative rate over the false‐positive rate. The soluble form of klotho can directly regulate the production and secretion of FGF‐23 but was not measured.
CONCLUSIONS
We found a positive association of dp‐ucMGP with long‐term incidence and progression of AVC and MAC, a positive association of FGF‐23 with MAC but not AVC, and an inverse association of fetuin‐A with AVC but not MAC. These findings support the notion that proper evaluation of vitamin K supplementation for cardiac calcification prevention should target individuals with high dp‐ucMGP levels. The present results also provide impetus for investigating the differential associations of FGF‐23 and fetuin‐A with AVC and MAC, their underlying mechanisms, and their potential for therapeutic manipulation.
Sources of Funding
Funding for this study was, in part, from an American Heart Association Mentored and Clinical Population Research Award 17MCPRP33630098 and the Montefiore Medical Center Division of Cardiology (A.E.B.). A.E.B. acknowledges support from the National Heart, Lung, and Blood Institute (K23 HL146982); the Resnick Emerging Scholar in Aging Award from the Albert Einstein College of Medicine; and philanthropic support from Dr Hazel J. Chambers. J.R.K. was supported by the National Heart, Lung, and Blood Institute (K24 HL135493). This research was supported by R01 HL071739, and MESA was supported by contracts N01‐HC‐95159, N01‐HC‐95160, N01‐HC‐95161, N01‐HC‐95162, N01‐HC‐95163, N01‐HC‐95164, N01‐HC‐95165, N01‐HC‐95166, N01‐HC‐95167, N01‐HC‐95168, and N01‐HC‐95169 from the National Heart, Lung, and Blood Institute; and by grants UL1‐TR‐000040, UL1‐TR‐001079, and UL1‐RR‐025005 from National Center for Research Resources. This publication was developed under a STAR research assistance agreement, No. RD831697 (MESA Air), awarded by the US Environmental Protection Agency. It has not been formally reviewed by the Environmental Protection Agency. The views expressed here are solely those of the authors, and the Environmental Protection Agency does not endorse any products or commercial services mentioned in this publication.
Disclosures
J.R.K. reports stock ownership in AbbVie, Abbott, Bristol‐Myers Squibb, Johnson & Johnson, Lilly, Medtronic, Merck, and Pfizer. A.E.B. served as site principal investigator for multicenter trials sponsored by Amgen, Arrowhead Pharmaceuticals, and CSL‐Behring, for which her institution received compensation; and reports an unrestricted educational grant from Zoll to the institution, honoraria from ClearView HealthCare LLC, and honoraria from Getinge and Zoll to the institution.
Supporting information
Tables S1–S2
Figures S1–S6
Acknowledgments
The authors thank the other investigators, the staff, and the participants of MESA for their valuable contributions. A full list of participating MESA investigators and institutions can be found at https://www.mesa‐nhlbi.org. Coauthor Russell P. Tracy, PhD, died April 6, 2026.
Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.042370
This manuscript was sent to John S. Ikonomidis, MD, PhD, Guest Associate Editor, for review by expert referees, editorial decision, and final disposition.
For Sources of Funding and Disclosures, see page 12.
References
- 1. Owens DS, Bartz TM, Buzkova P, Massera D, Biggs ML, Carlson SD, Psaty BM, Sotoodehnia N, Gottdiener JS, Kizer JR. Cumulative burden of clinically significant aortic stenosis in community‐dwelling older adults. Heart. 2021;107:1493–1502. doi: 10.1136/heartjnl-2021-319025 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Massera D, Kizer JR, Dweck MR. Mechanisms of mitral annular calcification. Trends Cardiovas Med. 2020;30:289–295. doi: 10.1016/j.tcm.2019.07.011 [DOI] [PubMed] [Google Scholar]
- 3. Abramowitz Y. Mitral annular calcification: incidental finding or an important entity that should not be disregarded? Trends Cardiovas Med. 2019;30:296–297. doi: 10.1016/j.tcm.2019.08.004 [DOI] [PubMed] [Google Scholar]
- 4. El‐Eshmawi A, Tang GHL, Sun E, et al. Contemporary surgical techniques for mitral valve replacement in extensive mitral annular calcification. JTCVS Techniques. 2023;22:1–12. doi: 10.1016/j.xjtc.2023.10.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Bortnick AE, Bartz TM, Ix JH, Chonchol M, Reiner A, Cushman M, Owens D, Barasch E, Siscovick DS, Gottdiener JS, et al. Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults. Heart. 2016;102:1826–1834. doi: 10.1136/heartjnl-2016-309404 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Bortnick AE, Buzkova P, Otvos J, et al. High‐density lipoprotein and long‐term incidence and progression of aortic valve calcification: The multi‐ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2022;42:1272–1282. doi: 10.1161/ATVBAHA.122.318004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Massera D, Bartz TM, Biggs ML, Sotoodehnia N, Reiner AP, Semba RD, Gottdiener JS, Psaty BM, Owens DS, Kizer JR. Traditional and novel risk factors for incident aortic stenosis in community‐dwelling older adults. Heart. 2023;110:57–64. doi: 10.1136/heartjnl-2023-322709 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Massera D, Buzkova P, Bortnick AE, et al. Bone mineral density and long‐term progression of aortic valve and mitral annular calcification: The multi‐ethnic study of atherosclerosis. Atherosclerosis. 2021;335:126–134. doi: 10.1016/j.atherosclerosis.2021.08.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Bortnick AE, Xu S, Kim RS, et al. Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The multi‐ethnic study of atherosclerosis. Atherosclerosis. 2019;285:79–86. doi: 10.1016/j.atherosclerosis.2019.04.215 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512. doi: 10.1056/NEJMoa1109034 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Smith JG, Luk K, Schulz CA, Engert JC, do R, Hindy G, Rukh G, Dufresne L, Almgren P, Owens DS, et al. Association of low‐density lipoprotein cholesterol‐related genetic variants with aortic valve calcium and incident aortic stenosis. Jama. 2014;312:1764–1771. doi: 10.1001/jama.2014.13959 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Afshar M, Luk K, Do R, et al. Association of Triglyceride‐Related Genetic Variants with Mitral Annular Calcification. J Am Coll Cardiol. 2017;69:2941–2948.doi: 10.1016/j.jacc.2017.04.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Zhao Y, Nicoll R, He YH, Henein MY. The effect of statins on valve function and calcification in aortic stenosis: a meta‐analysis. Atherosclerosis. 2016;246:318–324.doi: 10.1016/j.atherosclerosis.2016.01.023 [DOI] [PubMed] [Google Scholar]
- 14. Pawade TA, Doris MK, Bing R, White AC, Forsyth L, Evans E, Graham C, Williams MC, van Beek EJR, Fletcher A, et al. Effect of denosumab or Alendronic acid on the progression of aortic stenosis: a double‐blind randomized controlled trial. Circulation. 2021;143:2418–2427. doi: 10.1161/CIRCULATIONAHA.121.053708 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Diederichsen ACP, Lindholt JS, Möller S, Øvrehus KA, Auscher S, Lambrechtsen J, Hosbond SE, Alan DH, Urbonaviciene G, Becker SW, et al. Vitamin K2 and D in patients with aortic valve calcification: a randomized double‐blinded clinical trial. Circulation. 2022;145:1387–1397. doi: 10.1161/CIRCULATIONAHA.121.057008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81. doi: 10.1038/386078a0 [DOI] [PubMed] [Google Scholar]
- 17. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clini Investigation. 2004;113:561–568. doi: 10.1172/JCI200419081 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2‐Heremans‐Schmid glycoprotein/fetuin‐a is a systemically acting inhibitor of ectopic calcification. J Clini Investigation. 2003;112:357–366. doi: 10.1172/JCI17202 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V. Association of the Inactive Circulating Matrix Gla Protein with vitamin K intake, calcification, mortality, and cardiovascular disease: a review. Intern J Molecul Sci. 2019;20:20. doi: 10.3390/ijms20030628 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Médart L, Pottel H, Cavalier E. Dephosphorylated‐uncarboxylated matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol. 2014;15:145. doi: 10.1186/1471-2369-15-145 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Liu YP, Gu YM, Thijs L, Knapen MH, Salvi E, Citterio L, Petit T, Carpini SD, Zhang Z, Jacobs L, et al. Inactive matrix Gla protein is causally related to adverse health outcomes: a mendelian randomization study in a Flemish population. Hypertension. 2015;65:463–470. doi: 10.1161/HYPERTENSIONAHA.114.04494 [DOI] [PubMed] [Google Scholar]
- 22. Chirinos JA, Sardana M, Syed AA, Koppula MR, Varakantam S, Vasim I, Oldland HG, Phan TS, Drummen NEA, Vermeer C, et al. Aldosterone, inactive matrix gla‐protein, and large artery stiffness in hypertension. J Am Soc Hyperten: JASH. 2018;12:681–689. doi: 10.1016/j.jash.2018.06.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Venardos N, Bennett D, Weyant MJ, Reece TB, Meng X, Fullerton DA. Matrix Gla protein regulates calcification of the aortic valve. J Surgl Res. 2015;199:1–6. doi: 10.1016/j.jss.2015.04.076 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res. 2012;318:1040–1048. doi: 10.1016/j.yexcr.2012.02.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson‐Cohen C, Lima JAC, Polak JF, Blondon M, Ruzinski J, et al. Fibroblast growth factor‐23 and cardiovascular disease in the general population: the multi‐ethnic study of atherosclerosis. Circul Heart Failure. 2014;7:409–417. doi: 10.1161/CIRCHEARTFAILURE.113.000952 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Vidula MK, Orlenko A, Zhao L, Salvador L, Small AM, Horton E, Cohen JB, Adusumalli S, Denduluri S, Kobayashi T, et al. Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis. Eur J Heart Failure. 2021;23:2021–2032. doi: 10.1002/ejhf.2361 [DOI] [PubMed] [Google Scholar]
- 27. Jahnen‐Dechent W, Schinke T, Trindl A, Müller‐Esterl W, Sablitzky F, Kaiser S, Blessing M. Cloning and targeted deletion of the mouse fetuin gene. J Biolog Chem. 1997;272:31496–31503. doi: 10.1074/jbc.272.50.31496 [DOI] [PubMed] [Google Scholar]
- 28. Gelli R, Pucci V, Ridi F, Baglioni P. A study on biorelevant calciprotein particles: effect of stabilizing agents on the formation and crystallization mechanisms. J Colloid Interface Sci. 2022;620:431–441. doi: 10.1016/j.jcis.2022.04.025 [DOI] [PubMed] [Google Scholar]
- 29. Ix JH, Katz R, de Boer IH, Kestenbaum BR, Peralta CA, Jenny NS, Budoff M, Allison MA, Criqui MH, Siscovick D, et al. Fetuin‐a is inversely associated with coronary artery calcification in community‐living persons: the multi‐ethnic study of atherosclerosis. Clin Chem. 2012;58:887–895. doi: 10.1373/clinchem.2011.177725 [DOI] [PubMed] [Google Scholar]
- 30. Carr JJ, Nelson JC, Wong ND, McNitt‐Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population‐based studies: standardized protocol of multi‐ethnic study of atherosclerosis (MESA) and coronary artery risk development in young adults (CARDIA) study. Radiology. 2005;234:35–43. doi: 10.1148/radiol.2341040439 [DOI] [PubMed] [Google Scholar]
- 31. Budoff MJ, Takasu J, Katz R, Mao S, Shavelle DM, O'Brien KD, Blumenthal RS, Carr JJ, Kronmal R. Reproducibility of CT measurements of aortic valve calcification, mitral annulus calcification, and aortic wall calcification in the multi‐ethnic study of atherosclerosis. Acad Radiol. 2006;13:166–172. doi: 10.1016/j.acra.2005.09.090 [DOI] [PubMed] [Google Scholar]
- 32. Budoff MJ, Katz R, Wong ND, Nasir K, Mao SS, Takasu J, Kronmal R, Detrano RC, Shavelle DM, Blumenthal RS, et al. Effect of scanner type on the reproducibility of extracoronary measures of calcification: the multi‐ethnic study of atherosclerosis. Acad Radiol. 2007;14:1043–1049. doi: 10.1016/j.acra.2007.05.021 [DOI] [PubMed] [Google Scholar]
- 33. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504. doi: 10.1023/A:1012299115260 [DOI] [PubMed] [Google Scholar]
- 34. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, et al. Increased circulatory level of biologically active full‐length FGF‐23 in patients with hypophosphatemic rickets/osteomalacia. J Clini Endocrinol Metab. 2002;87:4957–4960. doi: 10.1210/jc.2002-021105 [DOI] [PubMed] [Google Scholar]
- 35. Kim S, Chang Y, Cho J, Hong YS, Zhao D, Kang J, Jung HS, Yun KE, Guallar E, Ryu S, et al. Life's simple 7 cardiovascular health metrics and progression of coronary artery calcium in a low‐risk population. Arteriosclerosis, Thrombosis, and Vasc Biol. 2019;39:826–833. doi: 10.1161/ATVBAHA.118.311821 [DOI] [PubMed] [Google Scholar]
- 36. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino RB Jr, Herrington DM. The relationship between blood pressure and C‐reactive protein in the multi‐ethnic study of atherosclerosis (MESA). J Am Coll Cardiol. 2005;46:1869–1874. doi: 10.1016/j.jacc.2005.07.050 [DOI] [PubMed] [Google Scholar]
- 37. Berlot AA, Fu X, Shea MK, et al. Matrix Gla protein and the long‐term incidence and progression of coronary artery and aortic calcification in the multi‐ethnic study of atherosclerosis. Atherosclerosis. 2024;392:117505. doi: 10.1016/j.atherosclerosis.2024.117505 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Zeb I, Li D, Nasir K, Katz R, Larijani VN, Budoff MJ. Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi‐ethnic study of atherosclerosis. Acad Radiol. 2012;19:811–818. doi: 10.1016/j.acra.2012.02.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Choi TY, Li D, Nasir K, Zeb I, Sourayanezhad S, Gupta M, Hacioglu Y, Mao SS, Budoff MJ. Differences in coronary atherosclerotic plaque burden and composition according to increasing age on computed tomography angiography. Acad Radiol. 2013;20:202–208. doi: 10.1016/j.acra.2012.09.017 [DOI] [PubMed] [Google Scholar]
- 40. Gassett AJ, Sheppard L, McClelland RL, et al. Risk factors for long‐term coronary artery calcium progression in the multi‐ethnic study of atherosclerosis. J Am Heart Assoc. 2015;4:e001726. doi: 10.1161/jaha.114.001726 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Fraser JD, Price PA. Lung, heart, and kidney express high levels of mRNA for the vitamin K‐dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma‐carboxylase. J Biol Chem. 1988;263:11033–11036. doi: 10.1016/S0021-9258(18)37912-2 [DOI] [PubMed] [Google Scholar]
- 42. Akin F, Celik O, Altun I, Ayca B, Diker VO, Satılmıs S, Sahin C. Relationship of fibroblast growth factor 23 and fetuin‐‐a to coronary atherosclerosis. J Diab Compl. 2015;29:550–555. doi: 10.1016/j.jdiacomp.2015.02.013 [DOI] [PubMed] [Google Scholar]
- 43. Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WMM, Boer JMA, Beulens JWJ. Matrix Gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diab Care. 2013;36:3766–3771. doi: 10.2337/dc13-0065 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Malhotra R, Nicholson CJ, Wang D, Bhambhani V, Paniagua S, Slocum C, Sigurslid HH, Lino Cardenas CL, Li R, Boerboom SL, et al. Matrix Gla protein levels are associated with arterial stiffness and incident heart failure with preserved ejection fraction. Arteriosclerosis, Thrombosis, and Vasc Biol. 2022;42:e61–e73. doi: 10.1161/ATVBAHA.121.316664 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann Internal Med. 2010;152:640–648. doi: 10.7326/0003-4819-152-10-201005180-00004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Ix JH, Shlipak MG, Katz R, Budoff MJ, Shavelle DM, Probstfield JL, Takasu J, Detrano R, O'Brien KD. Kidney function and aortic valve and mitral annular calcification in the multi‐ethnic study of atherosclerosis (MESA). Am J Kidney Dis: Offic J Natl Kidney Found. 2007;50:412–420. doi: 10.1053/j.ajkd.2007.05.020 [DOI] [PubMed] [Google Scholar]
- 47. Koos R, Brandenburg V, Mahnken AH, Muhlenbruch G, Stanzel S, Gunther RW, Floege J, Jahnen‐Dechent W, Kelm M, Kuhl HP. Association of fetuin‐a levels with the progression of aortic valve calcification in non‐dialyzed patients. Eur Heart J. 2009;30:2054–2061. doi: 10.1093/eurheartj/ehp158 [DOI] [PubMed] [Google Scholar]
- 48. Kubota N, Testuz A, Boutten A, Robert T, Codogno I, Duval X, Tubiana S, Hekimian G, Arangalage D, Cimadevilla C, et al. Impact of fetuin‐a on progression of calcific aortic valve stenosis ‐ The COFRASA ‐ GENERAC study. Int J Cardiol. 2018;265:52–57. doi: 10.1016/j.ijcard.2018.03.070 [DOI] [PubMed] [Google Scholar]
- 49. Parker BD, Schurgers LJ, Vermeer C, Schiller NB, Whooley MA, Ix JH. The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: The heart and soul study. Atherosclerosis. 2010;210:320–325. doi: 10.1016/j.atherosclerosis.2009.11.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Capoulade R, Côté N, Mathieu P, Chan KL, Clavel MA, Dumesnil JG, Teo KK, Tam JW, Fournier D, Després JP, et al. Circulating levels of matrix gla protein and progression of aortic stenosis: a substudy of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Canadian J Cardiol. 2014;30:1088–1095. doi: 10.1016/j.cjca.2014.03.025 [DOI] [PubMed] [Google Scholar]
- 51. Shea MK, Berkner KL, Ferland G, Fu X, Holden RM, Booth SL. Perspective: evidence before enthusiasm‐a critical review of the potential cardiovascular benefits of vitamin K. Adv Nutr. 2021;12:632–646. doi: 10.1093/advances/nmab004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Berkner KL, Runge KW. Vitamin K‐dependent protein activation: Normal gamma‐glutamyl carboxylation and disruption in disease. Intern J Molecul Sci. 2022;23:23. doi: 10.3390/ijms23105759 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Sonderskov PS, Lindholt JS, Hallas J, et al. Association of aortic valve calcification and vitamin K antagonist treatment. Eur Heart J Cardiovasc Imaging. 2020;21:718–724. doi: 10.1093/ehjci/jeaa065 [DOI] [PubMed] [Google Scholar]
- 54. Yamamoto K, Koretsune Y, Akasaka T, Kisanuki A, Ohte N, Takenaka T, Takeuchi M, Yoshida K, Iwade K, Okuyama Y, et al. Effects of vitamin K antagonist on aortic valve degeneration in non‐valvular atrial fibrillation patients: prospective 4‐year observational study. Thromb Res. 2017;160:69–75. doi: 10.1016/j.thromres.2017.10.027 [DOI] [PubMed] [Google Scholar]
- 55. Brandenburg VM, Reinartz S, Kaesler N, Krüger T, Dirrichs T, Kramann R, Peeters F, Floege J, Keszei A, Marx N, et al. Slower Progress of aortic valve calcification with vitamin K supplementation: results from a prospective interventional proof‐of‐concept study. Circulation. 2017;135:2081–2083. doi: 10.1161/CIRCULATIONAHA.116.027011 [DOI] [PubMed] [Google Scholar]
- 56. Edmonston D, Grabner A, Wolf M. FGF23 and klotho at the intersection of kidney and cardiovascular disease. Nat Rev Cardiol. 2024;21:11–24. doi: 10.1038/s41569-023-00903-0 [DOI] [PubMed] [Google Scholar]
- 57. The E, Zhai Y, Yao Q, Ao L, Fullerton DA, Meng X. Molecular interaction of soluble klotho with FGF23 in the pathobiology of aortic valve lesions induced by chronic kidney disease. Int J Biol Sci. 2024;20:3412–3425. doi: 10.7150/ijbs.92447 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG, et al. Fetuin‐a and incident diabetes mellitus in older persons. JAMA. 2008;300:182–188. doi: 10.1001/jama.300.2.182 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Tables S1–S2
Figures S1–S6
